Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas

被引：4

作者：

Chougnet, Cecile N. ^{[1
]}

Schlumberger, Martin ^{[2
]}

Leboulleux, Sophie ^{[2
]}

Baudin, Eric ^{[2
]}

机构：

[1] Hop St Louis, Nucl Med Serv, 1 Ave Claude Vellefaud, F-75010 Paris, France

[2] Inst Gustave Roussy, Serv Med Nucl & Cancerol Endocrinienne, F-94805 Villejuif, France

来源：

BULLETIN DU CANCER | 2014年 / 101卷 / 09期

关键词：

targeted therapy; multiple endocrine neoplasia; medullary thyroid cancer; treatment; vandetanib; CANCER;

D O I：

10.1684/bdc.2014.2022

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Medullary thyroid cancer (MTC) is a rare cancer. Vandetanib, a RET tyrosine-kinase inhibitor, significantly increased progression free survival and is the first treatment approved in France for unresectable, locally advanced or metastatic MTC that is symptomatic or progressive. Most frequents adverse events are diarrhea, folliculitis and asthenia. The prolongation of the QT interval on electrocardiogram is frequent but in the most of cases not clinically relevant. A good selection of the patients who could benefit from this treatment and management of side effect are important for the risk-benefit assessment.

引用

页码：891 / 895

页数：5

共 16 条

[1] Somatic RAS Mutations Occur in a Large Proportion of Sporadic RET-Negative Medullary Thyroid Carcinomas and Extend to a Previously Unidentified Exon [J].

Boichard, A. ;

Croux, L. ;

Al Ghuzlan, A. ;

Broutin, S. ;

Dupuy, C. ;

Leboulleux, S. ;

Schlumberger, M. ;

Bidart, J. M. ;

Lacroix, L. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (10) :E2031-E2035

[2] Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time [J].

Chatal, Jean-Francois ;

Kraeber-Bodere, Francoise ;

Goldenberg, David M. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2165-2165

[3] Cabozantinib in Progressive Medullary Thyroid Cancer [J].

Elisei, Rossella ;

Schlumberger, Martin J. ;

Mueller, Stefan P. ;

Schoffski, Patrick ;

Brose, Marcia S. ;

Shah, Manisha H. ;

Licitra, Lisa ;

Jarzab, Barbara ;

Medvedev, Viktor ;

Kreissl, Michael C. ;

Niederle, Bruno ;

Cohen, Ezra E. W. ;

Wirth, Lori J. ;

Ali, Haythem ;

Hessel, Colin ;

Yaron, Yifah ;

Ball, Douglas ;

Nelkin, Barry ;

Sherman, Steven I. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) :3639-+

[4] Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels [J].

Giraudet, Anne Laure ;

Vanel, Daniel ;

Leboulleux, Sophie ;

Auperin, Anne ;

Dromain, Clarisse ;

Chami, Linda ;

Tovo, Noel Ny ;

Lumbroso, Jean ;

Lassau, Nathalie ;

Bonniaud, Guillaume ;

Hartl, Dana ;

Travagli, Jean-Paul ;

Baudin, Eric ;

Schlumberger, Martin .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (11) :4185-4190

[5] Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies [J].

Grande, Enrique ;

Kreissl, Michael C. ;

Filetti, Sebastiano ;

Newbold, Kate ;

Reinisch, Walter ;

Robert, Caroline ;

Schlumberger, Martin ;

Tolstrup, Laerke K. ;

Zamorano, Jose L. ;

Capdevila, Jaume .

ADVANCES IN THERAPY, 2013, 30 (11) :945-966

[6] Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association [J].

Kloos, Richard T. ;

Eng, Charis ;

Evans, Douglas B. ;

Francis, Gary L. ;

Gagel, Robert F. ;

Gharib, Hossein ;

Moley, Jeffrey F. ;

Pacini, Furio ;

Ringel, Matthew D. ;

Schlumberger, Martin ;

Wells, Samuel A., Jr. .

THYROID, 2009, 19 (06) :565-612

[7] Vandetanib for the Treatment of Thyroid Cancer [J].

Langmuir, P. B. ;

Yver, A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (01) :71-80

[8] Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions [J].

Morabito, Alessandro ;

Piccirillo, Maria Carmela ;

Falasconi, Fabiano ;

De Feo, Gianfranco ;

Del Giudice, Antonia ;

Bryce, Jane ;

Di Maio, Massimo ;

De Maio, Ermelinda ;

Normanno, Nicola ;

Perrone, Francesco .

ONCOLOGIST, 2009, 14 (04) :378-390

[9] Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy [J].

Oudoux, Aurore ;

Salaun, Pierre-Yves ;

Bournaud, Claire ;

Campion, Loic ;

Ansquer, Catherine ;

Rousseau, Caroline ;

Bardet, Stephane ;

Borson-Chazot, Francoise ;

Vuillez, Jean-Philippe ;

Murat, Arnaud ;

Mirallie, Eric ;

Barbet, Jacques ;

Goldenberg, David M. ;

Chatal, Jean-Francois ;

Kraeber-Bodere, Francoise .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (12) :4590-4597

[10] Medullary Thyroid Carcinoma [J].

Pacini, F. ;

Castagna, M. G. ;

Cipri, C. ;

Schlumberger, M. .

CLINICAL ONCOLOGY, 2010, 22 (06) :475-485

← 1 2 →